Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Muscarinic agonists alter the metabolism of amyloid precursor protein, leading to an increase in alpha-secretase cleavage and a decreased production of amyloidogenic peptides; suggesting that these compounds might modify the Alzheimer's disease process. A second therapeutic target in AD is the accumulation of stably phosphorylated tau into neurofibrillary tangles; an early event correlating with cognitive impairment. Glycogen synthase kinase-3 (GSK-3beta) phosphorylates tau and is inhibited via protein kinase C (PKC). As certain muscarinic receptors are linked to PKC, we examined the effect of a range of agonists on GSK-3beta phosphorylation of tau. In neurons a nonspecific muscarinic agonist, carbachol, reduced tau phosphorylation. In nonneuronal cells expressing the ml receptor a range of ml agonists reduced transiently-expressed tau phosphorylation and altered its microtubulebinding properties. These findings link the two pathological process of AD-APP metabolism and tau phosphorylation - and suggest that muscarinic and other cholinergic compounds might have disease-modifying properties.

Original publication




Journal article


J Neural Transm (Vienna)

Publication Date





1201 - 1212


Acetylcholine, Alzheimer Disease, Amyloid beta-Protein Precursor, Animals, Binding Sites, Calcium-Calmodulin-Dependent Protein Kinases, Carbachol, Cells, Cultured, Fetus, Glycogen Synthase Kinase 3, Glycogen Synthase Kinases, Lithium Chloride, Microtubules, Muscarinic Agonists, Neurons, Phosphorylation, Pyridines, Rats, Rats, Sprague-Dawley, Receptors, Muscarinic, Tetrazoles, Thiadiazoles, tau Proteins